Virax Biolabs Group Limited - (VRAX) closed at $1.19 on October 26, 2026, down 2.5% from the previous close, on volume of 9,599 shares (30-day average 146,996).
Data as of October 26, 2026.
No press releases found.
Market Chameleon (Thu, 9-Jul 7:43 AM ET)
Market Chameleon (Thu, 9-Jul 3:50 AM ET)
VRAX’s Cash Surpasses Market Value: Virax Biolabs Sets 2026 Milestones After Major Clinical Progress
Market Chameleon (Wed, 3-Dec 4:51 AM ET)
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Virax Biolabs Group Limited - trades on the NASDAQ stock market under the symbol VRAX.
As of October 26, 2026, VRAX stock price declined to $1.19 with 9,599 million shares trading.
VRAX has a beta of 3.04, meaning it tends to be more sensitive to market movements. VRAX has a correlation of 0.07 to the broad based SPY ETF.
VRAX has a market cap of $948,355.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, VRAX traded as high as $225.00 and as low as $1.15.
VRAX has underperformed the market in the last year with a price return of -91.9% while the SPY ETF gained +15.1%. VRAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.7% and -36.4%, respectively, while the SPY returned +3.9% and -1.7%, respectively.
VRAX support price is $1.10 and resistance is $1.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRAX shares will trade within this expected range on the day.
